ClinicalTrials.gg
Not yet recruitingNCT07189468AI-PMPUpdated Sep 24, 2025

AI-based Progression and Medication Response Prediction Study in Parkinson's Disease

An observational study in PARKINSON DISEASE (Disorder), sponsored by University Hospital, Toulouse. Not yet recruiting at 4 sites in 4 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by University Hospital, Toulouse · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Parkinson Disease by University Hospital, Toulouse — 7 open to participants now, 7 under way, 1 of them phase 3. Parkinson Disease · University Hospital, Toulouse.

Started
2025
with 1 other
Observational
8 of 33
2 open now
Registered
31st of 33
by date

Among the 33 studies in Parkinson Disease by University Hospital, Toulouse, this one is one of 2 that started in 2025, is one of 8 observational ones, and was the 31st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

7 of the 33 studies in Parkinson Disease by University Hospital, Toulouse are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Parkinson Disease by University Hospital, Toulouse, or all of them as a file.
02

Study summary

The study aims to provide initial PoC validation data of two AI models to predict disease progression and treatment side effects in PD patients using as input patients' demographic, clinical and genetic information, as well as digital biomarker measurements in daily living collected via a smartwatch and a mobile application.

03

Conditions studied

  • PARKINSON DISEASE (Disorder)

Browse trials for

Keywords

  • AI
  • Parkinson disease
  • smartwatch
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Parkinson's disease patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parkinson's disease diagnosis according to MDS criteria (Postuma et al., 2015)
  • Disease duration ranging from 5 to 10 years
  • Age 40-80
  • Patients in stages 2 and 3 of the Hoehn and Yahr (a functional disability scale) in the ON condition
  • The participant is using a compatible smartphone
  • Written

Exclusion criteria

Exclusion Criteria:

  • Atypical Parkinsonian Syndrome
  • device-aided treatments
  • Patients with >4 daily doses of L-DOPA
  • Daily levodopa equivalent dose > 1500 mg
  • Ongoing hallucinations requiring short-term treatment adjustment
  • Inability to provide or participate in the study
  • Inability to use the smartwatch and/or the mAI-Care app - as judged by investigator
  • Lacking motivation to participate in study procedures - as judged by investigator
  • Under adult autonomy protection system, legal guardianship or incapacitation
  • Pregnant and breast-feeding women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Parkinson's disease patients

    Parkinson's disease patients to be monitored via a smartwatch and a mobile application

    Device: Smartwatch and mobile application

Interventions

  • DeviceSmartwatch and mobile application

    Wearing a smartwatch and using a mobile application for one year

06

What researchers measure

Primary outcomes

  1. Classification performance of the Parkinson's disease (PD) progression prediction model

    Classification performance of the model in predicting observed motor disease progression, defined as a binary outcome: the condition of a patient is classified as worsened if either the Movement Disorder Society Unified Parkinson's Disease (MDS-UPDRS) rating scale part III score in ON-state increases by more than 3 points (\>3), or the Levodopa Equivalent Daily Dose (LEDD) increases by more than 10%.

    Time frame: Between baseline and 12 months

Secondary outcomes

  1. Usability of the mAI-Care app

    System Usability Scale score of end-users (PD patients)

    Time frame: 12 month visit

  2. Usability of the mAI-Insights app

    System Usability Scale score of end-users (clinicians)

    Time frame: 12 month visit

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Apr 2027, 17 months later.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 17 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Sep 24, 2025
StartEst.
Oct 6, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07189468
Collaborators
Aristotle Univ. of Thessaloniki (Greece)
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Oct 6, 2025 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Sep 24, 2025

Study contacts

Margherita FABBRI, MD
Contact
fabbri.m@chu-toulouse.fr
0561776039 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion